Thrombocytosis As a Prognostic Marker in Stage III and IV Serous Ovarian Cancer

Overview

Journal Obstet Gynecol Sci

Specialty Gynecology & Obstetrics

Date 2014 Dec 4

PMID 25469333

Citations 13

Authors

Antonia Digklia

Ioannis A Voutsadakis

Affiliations

Soon will be listed here.

Abstract

Objective: Thrombocytosis is an adverse prognostic factor in many types of cancer. We investigated if pre-treatment increased platelet counts provide prognostic information specifically in patients with stage III and IV serous ovarian cancer which is the most common clinical presentation of ovarian cancer.

Methods: Platelet number on diagnosis of stage III and IV serous ovarian adenocarcinoma was evaluated in 91 patients for whom there were complete follow-up data on progression and survival. Survival and progression free survival of patients with normal platelet counts (150-350 ×10(9)/L) was compared with that of patients with thrombocytosis (>350×10(9)/L) by χ(2) and logrank tests.

Results: The median age of the patients was 66 years-old. From the 91 patients, 52 (57.1%) had normal platelet counts (median, 273×10(9)/L; range, 153-350) at diagnosis of their disease and 39 patients (42.9%) had thrombocytosis (median, 463×10(9)/L; range, 354-631). In the group of patients with normal platelet counts, 24 of the 52 patients had died with a median survival of 43 months (range, 3-100). In the group of patients with thrombocytosis, 24 of the 39 patients had died with a median survival of 23 months (range, 4-79). In the entire group of 91 patients there was a statistically significant difference of the overall survival and progression-free survival between the two groups (logrank test P=0.02 and P=0.007, respectively).

Conclusion: In this retrospective analysis of stage III and IV ovarian cancer patients, thrombocytosis at the time of diagnosis had prognostic value regarding overall survival and progression-free survival.

Citing Articles

Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer.

Fu Y, Lin H, Ou Y, Wu C, Fu H BMC Cancer. 2024; 24(1):1377.

PMID: 39529011 PMC: 11552161. DOI: 10.1186/s12885-024-13087-8.

Pre-treatment thrombocytosis and ovarian cancer survival: A meta-analysis.

Pergialiotis V, Vogiatzi Vokotopoulou L, Vlachos D, Liontos M, Kontomanolis E, Thomakos N Eur J Obstet Gynecol Reprod Biol X. 2024; 22:100312.

PMID: 38745890 PMC: 11091518. DOI: 10.1016/j.eurox.2024.100312.

Effects of heat waves and cold spells on blood parameters: a cohort study of blood donors in Tianjin, China.

Gao Y, Liu Y, He J, Zhang Y, Wang T, Wu L Environ Health Prev Med. 2024; 29:25.

PMID: 38658361 PMC: 11058483. DOI: 10.1265/ehpm.24-00023.

Platelets, Thrombocytosis, and Ovarian Cancer Prognosis: Surveying the Landscape of the Literature.

Hufnagel D, Cozzi G, Crispens M, Beeghly-Fadiel A Int J Mol Sci. 2020; 21(21).

PMID: 33142915 PMC: 7663176. DOI: 10.3390/ijms21218169.

Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: an updated meta-analysis.

Zhang X, Zhao W, Yu Y, Qi X, Song L, Zhang C World J Surg Oncol. 2020; 18(1):191.

PMID: 32731872 PMC: 7391520. DOI: 10.1186/s12957-020-01952-2.

References

MacKay H, Brady M, Oza A, Reuss A, Pujade-Lauraine E, Swart A . Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010; 20(6):945-52. DOI: 10.1111/IGC.0b013e3181dd0110. View

Chan J, Teoh D, Hu J, Shin J, Osann K, Kapp D . Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008; 109(3):370-6. DOI: 10.1016/j.ygyno.2008.02.006. View

Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel R . Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost. 2003; 89(6):1098-106. View

Bleeker J, Hogan W . Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. Thrombosis. 2011; 2011:536062. PMC: 3200282. DOI: 10.1155/2011/536062. View

Karabuk E, Kose M, Hizli D, Taskin S, Karadag B, Turan T . Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study. J Gynecol Oncol. 2013; 24(2):160-6. PMC: 3644693. DOI: 10.3802/jgo.2013.24.2.160. View

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

Hwang S, Kim K, Cheong J, Kim H, An J, Hyung W . Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol. 2012; 38(7):562-7. DOI: 10.1016/j.ejso.2012.04.009. View

Heng D, MacKenzie M, Vaishampayan U, Bjarnason G, Knox J, Tan M . Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol. 2011; 23(6):1549-55. PMC: 3858023. DOI: 10.1093/annonc/mdr533. View

Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J . Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology. 2000; 58(2):169-74. DOI: 10.1159/000012095. View

10.

Labelle M, Begum S, Hynes R . Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011; 20(5):576-90. PMC: 3487108. DOI: 10.1016/j.ccr.2011.09.009. View

11.

Niers T, Richel D, Meijers J, Schlingemann R . Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One. 2011; 6(5):e19873. PMC: 3102663. DOI: 10.1371/journal.pone.0019873. View

12.

Brown K, Domin C, Aranha G, Yong S, Shoup M . Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg. 2005; 189(3):278-82. DOI: 10.1016/j.amjsurg.2004.11.014. View

13.

Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L . The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet. 2008; 279(1):53-6. DOI: 10.1007/s00404-008-0673-9. View

14.

Allensworth S, Langstraat C, Martin J, Lemens M, McGree M, Weaver A . Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer. Gynecol Oncol. 2013; 130(3):499-504. PMC: 3748213. DOI: 10.1016/j.ygyno.2013.05.038. View

15.

Li A, Madden A, Cass I, Leuchter R, Lagasse L, Karlan B . The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol. 2004; 92(1):211-4. DOI: 10.1016/j.ygyno.2003.09.002. View

16.

Mermer T, Terek M, Zeybek B, Ergenoglu A, Yeniel A, Ozsaran A . Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer. J Gynecol Oncol. 2012; 23(2):86-90. PMC: 3325354. DOI: 10.3802/jgo.2012.23.2.86. View

17.

Battinelli E, Markens B, Italiano Jr J . Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011; 118(5):1359-69. PMC: 3152500. DOI: 10.1182/blood-2011-02-334524. View

18.

Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H . Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004; 198(5):737-41. DOI: 10.1016/j.jamcollsurg.2004.01.022. View

19.

Stone R, Nick A, McNeish I, Balkwill F, Han H, Bottsford-Miller J . Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012; 366(7):610-8. PMC: 3296780. DOI: 10.1056/NEJMoa1110352. View

20.

Jelovac D, Armstrong D . Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011; 61(3):183-203. PMC: 3576854. DOI: 10.3322/caac.20113. View